BR0007647A - Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais - Google Patents

Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais

Info

Publication number
BR0007647A
BR0007647A BR0007647-3A BR0007647A BR0007647A BR 0007647 A BR0007647 A BR 0007647A BR 0007647 A BR0007647 A BR 0007647A BR 0007647 A BR0007647 A BR 0007647A
Authority
BR
Brazil
Prior art keywords
omeprazole
potassium salt
preparing
methoxy
pharmaceutical formulation
Prior art date
Application number
BR0007647-3A
Other languages
English (en)
Inventor
Maths Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0007647A publication Critical patent/BR0007647A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"SAL DE POTáSSIO DA FORMA B DE (S)-OMEPRAZOL, PROCESSOS PARA A PREPARAçãO DO MESMO, FORMULAçãO FARMACêUTICA, USO DO SAL DE POTáSSIO DA FORMA B DE (S)-OMEPRAZOL, E, MéTODO DE TRATAMENTO DE DISTúRBIOS GASTROINTESTINAIS". A presente invenção refere-se a nova forma de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1<UM>H<MV >-benzimidazol, conhecido sob o nome genérico omeprazol. Mais especificamente, ela referese a nova forma cristalina do sal de potássio do (S)-enanciómero de 5-metoxi-2-[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfnil]-1<UM>H<MV >-benzimidazol. A presente invenção também refere-se a processo para preparação de tal forma do sal de potássio de (S)-omeprazol e composições farmacêuticas contendo ele.
BR0007647-3A 1999-01-28 2000-01-18 Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais BR0007647A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound
PCT/SE2000/000087 WO2000044744A1 (en) 1999-01-28 2000-01-18 Potassium salt of ($i(s))-omeprazole

Publications (1)

Publication Number Publication Date
BR0007647A true BR0007647A (pt) 2001-10-16

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007647-3A BR0007647A (pt) 1999-01-28 2000-01-18 Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais

Country Status (40)

Country Link
US (1) US6511996B1 (pt)
EP (1) EP1149090B1 (pt)
JP (1) JP2002535401A (pt)
KR (1) KR100624054B1 (pt)
CN (1) CN1231477C (pt)
AR (1) AR022425A1 (pt)
AT (1) ATE236899T1 (pt)
AU (1) AU768676B2 (pt)
BG (1) BG65060B1 (pt)
BR (1) BR0007647A (pt)
CA (1) CA2357744C (pt)
CZ (1) CZ300504B6 (pt)
DE (1) DE60002042T2 (pt)
DK (1) DK1149090T3 (pt)
DZ (1) DZ3001A1 (pt)
EE (1) EE04240B1 (pt)
EG (1) EG23980A (pt)
ES (1) ES2193937T3 (pt)
HK (1) HK1041259B (pt)
HU (1) HU226766B1 (pt)
ID (1) ID30095A (pt)
IL (1) IL144107A0 (pt)
IS (1) IS2019B (pt)
MY (1) MY119095A (pt)
NO (1) NO319719B1 (pt)
NZ (1) NZ512804A (pt)
PL (1) PL197881B1 (pt)
PT (1) PT1149090E (pt)
RS (1) RS50200B (pt)
RU (1) RU2237666C2 (pt)
SA (1) SA00200895B1 (pt)
SE (1) SE9900274D0 (pt)
SI (1) SI1149090T1 (pt)
SK (1) SK285626B6 (pt)
TN (1) TNSN00017A1 (pt)
TR (1) TR200102138T2 (pt)
TW (1) TWI269795B (pt)
UA (1) UA71594C2 (pt)
WO (1) WO2000044744A1 (pt)
ZA (1) ZA200105526B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
SG181535A1 (en) 2009-12-08 2012-07-30 Codexis Inc Synthesis of prazole compounds
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
CN1138534C (zh) 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
AU768676B2 (en) 2003-12-18
RU2237666C2 (ru) 2004-10-10
TNSN00017A1 (fr) 2005-11-10
SK285626B6 (sk) 2007-05-03
DK1149090T3 (da) 2003-06-30
EE04240B1 (et) 2004-02-16
NZ512804A (en) 2003-07-25
EG23980A (en) 2008-02-27
DE60002042T2 (de) 2003-12-18
IL144107A0 (en) 2002-05-23
CA2357744C (en) 2009-06-16
DZ3001A1 (fr) 2004-03-27
PL197881B1 (pl) 2008-05-30
HUP0105313A2 (hu) 2002-05-29
KR100624054B1 (ko) 2006-09-18
EP1149090B1 (en) 2003-04-09
HUP0105313A3 (en) 2003-01-28
EE200100395A (et) 2002-10-15
BG105841A (en) 2002-04-30
NO20013665D0 (no) 2001-07-26
NO319719B1 (no) 2005-09-05
HK1041259B (zh) 2003-10-24
ATE236899T1 (de) 2003-04-15
TR200102138T2 (tr) 2001-12-21
ES2193937T3 (es) 2003-11-16
UA71594C2 (uk) 2004-12-15
HU226766B1 (en) 2009-09-28
SE9900274D0 (sv) 1999-01-28
AU2469400A (en) 2000-08-18
CN1231477C (zh) 2005-12-14
RS50200B (sr) 2009-07-15
ZA200105526B (en) 2002-10-04
TWI269795B (en) 2007-01-01
JP2002535401A (ja) 2002-10-22
IS5989A (is) 2001-07-05
SA00200895B1 (ar) 2006-11-11
MY119095A (en) 2005-03-31
NO20013665L (no) 2001-07-26
CZ300504B6 (cs) 2009-06-03
KR20010101699A (ko) 2001-11-14
EP1149090A1 (en) 2001-10-31
SK10372001A3 (sk) 2002-02-05
CA2357744A1 (en) 2000-08-03
SI1149090T1 (en) 2003-10-31
DE60002042D1 (de) 2003-05-15
IS2019B (is) 2005-06-15
HK1041259A1 (en) 2002-07-05
CZ20012730A3 (cs) 2002-02-13
AR022425A1 (es) 2002-09-04
PT1149090E (pt) 2003-07-31
WO2000044744A1 (en) 2000-08-03
BG65060B1 (bg) 2007-01-31
ID30095A (id) 2001-11-01
CN1339034A (zh) 2002-03-06
YU53801A (sh) 2004-07-15
US6511996B1 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
BR0007647A (pt) Sal de potássio de forma b de (s) -omeprazol, processo para a preparação do mesmo, formulação farmacêutica, uso do sal de potássio da forma b de (s) -omeprazol, e, método de tratamento de distúrbios gastrointestinais
BR9809509A (pt) Composto, processo para preparação e uso do sal de magnésio de s-omeprazol triidratado, composição farmacêutica, e, processo para tratamento de uma condição relacionada com acidez gástrica
BR9816067A (pt) Forma a de omeprazol, omeprazol, processo para a preparação da forma a de omeprazol, formulação farmacêutica, uso de omeprazol, e, método de tratamento de distúrbios gastrointestinais.
AR013350A1 (es) Sal de sodio de omeprazol forma b, proceso para su preparacion, formulacion farmaceutica, y uso de dicha sal para la fabricacion de medicamentos.
AR103295A2 (es) Compuesto cristalino de benzimidazol, composición farmacéutica que lo comprende y método para la manufactura de dicha composición
DK0414847T3 (da) Anvendelse af omeprazol som antimikrobielt middel
AR010361A1 (es) &#34;S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS&#34;
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
BR0209103A (pt) Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.